tetano
Editor, Senior Moderator
Lancet Infect Dis
. 2020 Dec 14;S1473-3099(20)30847-1.
doi: 10.1016/S1473-3099(20)30847-1. Online ahead of print.
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
Philipp Koehler[SUP] 1 [/SUP], Matteo Bassetti[SUP] 2 [/SUP], Arunaloke Chakrabarti[SUP] 3 [/SUP], Sharon C A Chen[SUP] 4 [/SUP], Arnaldo Lopes Colombo[SUP] 5 [/SUP], Martin Hoenigl[SUP] 6 [/SUP], Nikolay Klimko[SUP] 7 [/SUP], Cornelia Lass-Fl?rl[SUP] 8 [/SUP], Rita O Oladele[SUP] 9 [/SUP], Donald C Vinh[SUP] 10 [/SUP], Li-Ping Zhu[SUP] 11 [/SUP], Boris B?ll[SUP] 12 [/SUP], Roger Br?ggemann[SUP] 13 [/SUP], Jean-Pierre Gangneux[SUP] 14 [/SUP], John R Perfect[SUP] 15 [/SUP], Thomas F Patterson[SUP] 16 [/SUP], Thorsten Persigehl[SUP] 17 [/SUP], Jacques F Meis[SUP] 18 [/SUP], Luis Ostrosky-Zeichner[SUP] 19 [/SUP], P Lewis White[SUP] 20 [/SUP], Paul E Verweij[SUP] 21 [/SUP], Oliver A Cornely[SUP] 22 [/SUP], European Confederation of Medical Mycology; International Society for Human Animal Mycology; Asia Fungal Working Group; INFOCUS LATAM/ISHAM Working Group; ISHAM Pan Africa Mycology Working Group; European Society for Clinical Microbiology; Infectious Diseases Fungal Infection Study Group; ESCMID Study Group for Infections in Critically Ill Patients; Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy; Medical Mycology Society of Nigeria; Medical Mycology Society of China Medicine Education Association; Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology; Association of Medical Microbiology; Infectious Disease Canada
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.
. 2020 Dec 14;S1473-3099(20)30847-1.
doi: 10.1016/S1473-3099(20)30847-1. Online ahead of print.
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
Philipp Koehler[SUP] 1 [/SUP], Matteo Bassetti[SUP] 2 [/SUP], Arunaloke Chakrabarti[SUP] 3 [/SUP], Sharon C A Chen[SUP] 4 [/SUP], Arnaldo Lopes Colombo[SUP] 5 [/SUP], Martin Hoenigl[SUP] 6 [/SUP], Nikolay Klimko[SUP] 7 [/SUP], Cornelia Lass-Fl?rl[SUP] 8 [/SUP], Rita O Oladele[SUP] 9 [/SUP], Donald C Vinh[SUP] 10 [/SUP], Li-Ping Zhu[SUP] 11 [/SUP], Boris B?ll[SUP] 12 [/SUP], Roger Br?ggemann[SUP] 13 [/SUP], Jean-Pierre Gangneux[SUP] 14 [/SUP], John R Perfect[SUP] 15 [/SUP], Thomas F Patterson[SUP] 16 [/SUP], Thorsten Persigehl[SUP] 17 [/SUP], Jacques F Meis[SUP] 18 [/SUP], Luis Ostrosky-Zeichner[SUP] 19 [/SUP], P Lewis White[SUP] 20 [/SUP], Paul E Verweij[SUP] 21 [/SUP], Oliver A Cornely[SUP] 22 [/SUP], European Confederation of Medical Mycology; International Society for Human Animal Mycology; Asia Fungal Working Group; INFOCUS LATAM/ISHAM Working Group; ISHAM Pan Africa Mycology Working Group; European Society for Clinical Microbiology; Infectious Diseases Fungal Infection Study Group; ESCMID Study Group for Infections in Critically Ill Patients; Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy; Medical Mycology Society of Nigeria; Medical Mycology Society of China Medicine Education Association; Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology; Association of Medical Microbiology; Infectious Disease Canada
Affiliations
- PMID: 33333012
- DOI: 10.1016/S1473-3099(20)30847-1
Abstract
Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.